This study evaluates the reversal effects of graphene oxide (GO) used as a carrier for adriamycin (ADR) in cancer drug resistance, and provides a preliminary investigation into the reversal mechanism. ADR was loaded onto the GO surface (ADR-GO) by physical mixing and drug loading content was found to be high, up to 93.6%. In vitro releases of ADR from ADR-GO were studied using a dialysis method, and they exhibited a significant pH-sensitive property. Cell experiments showed that GO significantly enhanced the accumulation of ADR in MCF-7/ADR cells (an ADR resistant breast cancer cell line) and exhibited much higher cytotoxicity than free ADR, suggesting that ADR-GO could effectively reverse ADR resistance of MCF-7/ADR, with the reversal index reaching 8.35. Microscopy studies found that GO could effectively carry drug molecules into cells in both endocytosis-dependent and independent manners. In conclusion, use of GO as a carrier for chemotherapeutic agents is favorable for the treatment of drug resistant cancers.
Introduction
Cancer is a leading cause of death. Breakthroughs in biomedical research have dramatically reduced threats from infection, cardiovascular disease, metabolic diseases etc. However, the survival rate of cancer patients has not improved significantly in the last three decades. Chemotherapy, along with surgery and radiotherapy, is one of the most effective treatments for cancer. However, the efficacy of chemotherapies is limited by multi-drug resistance (MDR) acquired during long-term treatment [1] . Several molecular mechanisms of MDR have been revealed. In drug resistant cells, expression of a transporter P-glycoprotein (P-gp), encoded by a multi-drug resistance gene (MDR1), is enhanced, so that drugs are actively pumped out of cells and fail to exert their functions [2] . Drug resistant cells also acquire enhanced detoxification activities which convert cancer drugs into non-toxic derivatives [3] [4] [5] . Many attempts to modulate MDR1 activity during chemotherapy have failed due to undesired toxicity and poor specificity [6] [7] [8] [9] . Conventional methods have not yielded an effective solution to this problem.
Advances in nanotechnology provide new approaches to reverse MDR in cancer treatment [10] . A number of nanotherapeutic systems, such as liposomes, polyalkylcyanoacrylate nanoparticles, and polymeric micelle systems, have been designed in recent decade and exhibited certain potentials for treating MDR cancer [11] . For example, a multi-functional nanoparticle system co-encapsulated chemotherapeutic agents and MDR inhibitors, therefore decreasing the toxicity of inhibitors and increasing the therapeutic effects [12, 13] ; some nanoparticles have been decorated with endogenous ligands, which facilitated cancer cell specific drug delivery via endocytosis, and therefore drugs bypassed the identification by P-gp and accumulated inside cells [14, 15] ; pH-responsive micelles were designed to achieve controlled drug release and endosomal escape, which were both vital in overcoming various MDR factors [16, 17] . However, these attempts are still in the laboratory stage and not yet usable due to problems of in vivo efficiency, stability and safety, etc.
Graphene oxide (GO), discovered in 2004, shows potential advantages in energy, electronics, molecular sensors and catalysis [18] . Recently, several reports have suggested that GO could be a novel and promising drug carrier [19, 20] . Compared to conventional drug carriers, GO shows certain marked advantages with high drug loading efficiency, targeting specificity, and intelligent controlled release, probably due to its high aspect ratio and abundant surface chemistry [21] . Dai et al reported that PEGylated nanographene oxide loaded an aromatic anticancer drug with high efficiency without obvious toxicity [19] . Nanographene oxide functionalized with specific antibodies could specifically deliver adriamycin to cancer cells and enhance its therapeutic effects [20] . Bao et al, prepared chitosan-grafted GO sheets and found that this novel nanocarrier was able to load and deliver both anticancer drugs and genes [22] . Furthermore, Yang et al prepared adriamycin-loaded multi-functionalized GO nanoparticles with a dual magnetic and molecular targeting delivery system and used them to enhance the effect of targeted drug delivery and to realize intelligently controlled drug release [23] .
In view of its unique physical shape and chemical composition, we hypothesize that GO could be used as an effective drug carrier to treat MDR cancer cells. In this study, ADR was chosen as the model anticancer drug to be loaded onto the GO surface via π -π stacking, and its release from GO sheets was studied in vitro. The efficacy of this ADR-loaded GO nanosystem (ADR-GO) on MCF-7 breast cancer cells and ADR resistant MCF-7 (MCF-7/ADR) cells was systematically investigated by using 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt (MTT) assay, flow cytometry and confocal and fluorescence microscopy technologies. Moreover, the reversal mechanism was also preliminarily investigated based on the method of cell entry of GO in this study.
Experimental details

Materials
MTT and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich (St Louis, MO, USA). Adriamycin hydrochloride (ADR·HCl) was purchased from Hisun Pharmaceutical Co. Ltd (Zhejiang, China). GO with a carboxylic acid group content of 8.1% was kindly provided by Dr Y S Chen (Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, China). 1,1 -Dioctadecyl-3,3,3 ,3 -tetramethylindo-carbocyanine perchlorate (Dil) was purchased from Molecular Probes, Inc. (Carlsbad, CA, USA). All other chemicals were of analytical grade.
The MCF-7 breast cancer cell line and its ADR resistant cell line MCF-7/ADR (a gift from the Detroit Hospital, Detroit, MI, USA) were maintained in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum (Hyclone, Logan, UT, USA), 100 U ml −1 penicillin and 100 U ml −1 streptomycin at 37 • C under 5% CO 2 . The cells were subcultured two to three times per week with 0.25% trypsin-EDTA (Gibco BRL, Rockville, MD, USA). The MCF-7/ADR cells were maintained continuously in 0.5 µM ADR.
Preparation of ADR-and Dil-loaded graphene oxide (ADR-GO and Dil-GO)
GO (10 mg) was sonicated in 10 ml dilute NaOH aqueous solution (pH = 12) for 3 h to transform the carboxylic acid groups to carboxylate anions, and then neutralized by dilute hydrochloric acid to the neutral pH value. The resulting solution was purified by repeated rinsing and centrifugation, and finally brought to a concentration of 1 mg ml −1 . An atomic force microscope (AFM; Veeco, Nanoscope IV, Digital Instruments, New York, USA) was used to characterize the size and morphology of the above GO samples.
In contrast to a previous method [24] , we used an improved method to prepare ADR-GO in this study. Briefly, ADR·HCl (10 mg) was firstly dissolved in the mixture solution of DMSO (2 ml) and triethyl-amine (6 µl), and then stirred in the dark for 12 h to remove hydrochloride. Subsequently, 1 ml ADR-DMSO solution (5 mg ml −1 ) was added to 5 ml GO aqueous solution (1 mg ml −1 ) under sonication for 0.5 h, followed by stirring overnight at room temperature, avoiding light. The unloaded ADR molecules were removed by centrifugation filtration through 100 kDa MWCO Amicon filters (Millipore, Billerica, MA, USA) and washed away with water over five times until there was no noticeable color in the filtrate solution. The ADR concentration in the filtrate was measured using a standard ADR concentration curve generated with a RF-4500 fluorescence spectrophotometer (Shimadzu, Kyoto, Japan), and the excitation wavelength (kex) and the emission wavelength (kem) were set at 470 and 585 nm, respectively. Thus, the ADR loading content of ADR-GO could be obtained by calculation. Dil-GO was prepared in a similar method, but the feed weight ratio of Dil and GO was 1/100.
In vitro release of ADR from ADR-GO
ADR in vitro releases from ADR-GO were studied in phosphate buffered saline (PBS) solutions (pH = 5.0, 7.2 and 9.0) by the dialysis method [25] . Briefly, the ADR-GO aqueous solutions were respectively placed into Visking dialysis tubing with a molecular weight cutoff of 12-14 kDa (Millipore) and dialyzed against 50 ml of PBS solutions at 37 ± 0.2 • C in an air-bath shaker at 50 rpm. Then, 0.5 ml of the release medium was collected and replaced with an equal volume of the fresh release medium at predefined time intervals. Amounts of ADR released were measured using the same method as described above.
In vitro cytotoxicity assay
The cytotoxicity assay was carried out using the MTT cell proliferation assay. Briefly, 5 × 10 3 MCF-7 or MCF-7/ADR cells were respectively seeded onto 96-well culture plates and cultured for 24 h. The original medium (200 µl) was removed and replaced with ADR-GO or free ADR solutions at different concentrations and incubated for 48 h. 20 µl of MTT reagent (5 mg ml −1 ) was then added to each well and incubated for a further 4 h. The culture medium was removed and DMSO (150 µl) was added. The plate was shaken for 20 s and the absorbance measured immediately at 570 nm using an ELX800 absorbance microplate reader (Bio-tek EPOCH, Winooski, VT, USA). The cytotoxicity was expressed as a percentage of the control, and the IC 50 value was determined as the ADR concentration required to reduce the absorbance to 50% of that in untreated control wells.
Cellular uptake of ADR-GO
Flow cytometry was used to assess the accumulation of ADR-GO in MCF-7 and MCF-7/ADR cells, and free ADR was used as the control. Briefly, MCF-7 and MCF-7/ADR cells were plated in a six-well culture dish and cultured at 37 • C in 5% CO 2 until 80% confluent. Cells were rinsed twice with PBS (pH = 7.4) and pre-incubated for 1 h with serum-free medium. Free ADR or ADR-GO solution was then added at an ADR concentration of 10 µg ml −1 and incubated for 10 min to 4 h. The cells were washed three times with PBS to remove any free drug or ADR-GO nanomaterials, detached with 0.25% trypsin, and centrifuged at 1000 rpm. Supernatants were discarded, and the cells were re-suspended with PBS containing 0.1% bovine serum albumin (BSA) and introduced into a fluorescence-activated cell sorting Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA) for the fluorescence intensity analysis of intracellular ADR (excitation 488 nm, emission 575 nm). The data presented are the mean fluorescent signals for 10 000 cells.
Intracellular localization of ADR-GO
Confocal microscopy was used to visualize the intracellular localization of ADR-GO in MCF-7 and MCF-7/ADR cells, and free ADR was used as the control. Briefly, cells (1 × 10 5 ) in 500 µl culture medium were seeded into 12-well chambers and incubated overnight on a glass coverslip at 37 • C. Cells were washed twice, pre-incubated at 37 • C for 1 h in the serum-free medium, and incubated in the presence of free ADR or ADR-GO for 10 min to 4 h. The cells were washed three times with PBS containing 0.1% BSA and fixed in 3.7% paraformaldehyde solution at 4 • C for 15 min. For observation of nuclear localization of free ADR or ADR-GO, the cells were incubated with 1 µg ml −1 4 ,6-diamidino-2-phenylindole (DAPI) nuclear dye (D9564, Sigma-Aldrich) for 5 min and washed twice with PBS. The samples were then mounted with a mixture of PBS/glycerol (1:9), and fluorescence was monitored in the following two channels: red (for ADR; excitation 488 nm, emission 575 nm) and blue (for DAPI; excitation 364 nm, emission 454 nm). The images were acquired using Leica TCS SP5 confocal microscope (Leica Microsystems, Mannheim, Germany).
Cell entry of ADR-GO
Fluorescence microscopy was used to study the cell entry pathway of ADR-GO in MCF-7 and MCF-7/ADR cells. Briefly, the cells were cultured for 24 h and then directly incubated with ADR-GO for 10 min to 4 h at 4 and 37 • C in the dark and gently washed twice with PBS. The cells were then kept in PBS solution and directly visualized with an automated inverted fluorescence microscope (Olympus IX71, Tokyo, Japan).
Moreover, MCF-7/ADR cells were also treated with free Dil or Dil-GO for 10 min to 4 h in the dark and washed twice with PBS, and then directly visualized with an Olympus IX71 inverted fluorescence microscope.
Statistical analysis
All data were reported as mean ± standard deviation. Statistical analysis was performed using analysis of variables (ANOVA), and p < 0.05 was considered statistically significant.
Results and discussion
3.1. ADR was loaded onto the GO surface with high content and released in response to the environmental pH.
GO consists of intact graphitic regions interspersed with sp 3 -hybridized carbons containing carboxyl, hydroxyl, and epoxide functional groups on the sheet surface and sp 2 -hybridized carbons on the aromatic network, thus it can effectively load drug molecules, especially those with π -conjugated structures, by intermolecular forces [26] . In this study, the anthracycline antibiotic ADR was used as a model anticancer drug to be loaded onto the GO surface by a simple method. GO was first processed by sonication to obtain the small-sized graphene sheets, and then mixed with doxorubicin (DOX)-DMSO solution that was desalinated to prepare ADR-GO. The morphologies of GO and ADR-GO were characterized by atomic force microscopy. Most GO sheets were smaller than 100 nm and their thickness ranged from 0.8 to 1.5 nm, suggesting a single-or double-layered graphene structure ( figure 1(a) ). However, ADR-GO showed a larger size, a wider size distribution, and a greater thickness ( figure 1(b) ). Compared with the previous method [24] , ADR-GO prepared from desalted ADR in this study exhibited better stability. No aggregation was observed on storage for more than 1 month. The mixed feed ratio of 1/1 for ADR and GO was chosen to prepare ADR-GO and the drug loading content reached up to 93.6% (0.468 mg ADR/mg GO), far exceeding the loading efficacy of many polymer vesicles.
ADR releases from ADR-GO in vitro were investigated in PBS solutions with different pH values (5.0, 7.2 and 9.0), and the release profiles are shown in figure 2 . Obviously, ADR-GO exhibited a pH-sensitive drug release property. The ADR release rate at pH 5.0 was significantly faster than that at pH 7.2 or 9.0, such as 16.3% of total loaded ADR released at pH 5.0 in 46 h, but only 7.4 and 5.3% of total loaded ADR released at pH 7.2 and 9.0, respectively. Moreover, the release rate at pH 7.2 was slightly slower than that at pH 9.0 after 8 h. As we previously reported [24] , there were abundant hydrogen bonds between ADR (−OH, −NH 2 ) and GO sheets (−OH, −COOH) in addition to the π -π stacking and hydrophobic interactions. These hydrogen bonds increased in strength in the following conditions: acidic < basic < neutral, which probably contributed to the difference in ADR release rates at different pHs. Taken together, the pH-sensitive drug release property favors the stability of ADR-GO in blood circulation and rapid release of ADR from ADR-GO after entering cancer cells through endocytosis, which we discuss in the latter part of this study.
Drug resistant breast cancer cells were sensitive to treatment with ADR-GO
The cytotoxicities of free ADR and ADR-GO were estimated in MCF-7 (ADR sensitive) and MCF-7/ADR (ADR resistant) cells using MTT assay, and the cells were cultured with the drug treatments for 48 h. The results are presented in figure 3 . Compared to MCF-7 cells, the cytotoxicity of free ADR on MCF-7/ADR cells substantially decreased (figures 3(a) and (c)) and the IC 50 value increased from 1.28 ± 0.26 to 13.95 ± 0.53 µg ml −1 (figures 3(b) and (d)), which was due to the drug resistance of MCF-7/ADR cells. Thus, the resistance index, calculated as a ratio between IC 50 values for MCF-7/ADR and MCF-7 cells, was 10.9. However, ADR-GO also showed a relatively high cytotoxicity on MCF-7/ADR cells, and IC 50 of ADR was only 1.67 ± 0.28 µg ml −1 ( figure 3(d) ). Therefore, the reversal index, calculated as a ratio between IC 50 values of free ADR and ADR-GO for MCF-7/DOX cells, reached up to 8.35. Moreover, GO showed no detectable cytotoxicity in the concentration range between 0.1 and 10 µg ml −1 (the data were omitted), consistent with previous reports [27, 28] . All the above results indicated that ADR-GO effectively reversed the drug resistance of MCF-7/ADR cells. * P < 0.05 and * * P < 0.01 in comparison to free ADR.
The uptake of ADR in MCF-7/ADR cells was significantly enhanced by GO loading
Based on the intrinsic fluorescence from ADR, flow cytometry was used to evaluate the kinetics of drug uptakes in both MCF-7 and MCF-7/ADR cells treated with ADR (10 µg ml −1 ) for 10 min to 4 h. The fluorescence images and the corresponding kinetic curves (fluorescence intensity versus time) are plotted in figure 4 . There was no significant difference between the cellular uptakes of free ADR and ADR-GO in MCF-7 cells, which both reached saturation after 1 h, designated as 100% (figures 4(a) and (c)). However, the uptake of ADR was obviously enhanced in MCF-7/ADR cells by GO loading, compared to that of free ADR (figures 4(b) and (d)). For example, the total amount of ADR-GO in MCF-7/ADR cells reached 79.4% of that in MCF-7 cells at 4 h, but only 28.2% corresponded to free ADR at the same time, which meant that more drug was retained in MCF-7/ADR cells and exerted therapeutic effects by GO loading. Taken together, the results from kinetics studies further confirmed that ADR-GO could effectively reverse drug resistance of MCF-7/ADR cells by increasing cellular uptake of ADR.
ADR was mainly located in the nucleus of breast cancer cells
Confocal microscopy was utilized to characterize the subcellular locations of drugs in MCF-7 and MCF-7/ADR cells. Free ADR and ADR-GO with the same drug concentration were both mainly located in the nucleus of MCF-7 and MCF-7/ADR cells, due to the high affinity of the ADR molecule for DNA [29] (figures 5(a)-(c) ). In MCF-7/ADR cells, the red fluorescence of free ADR was obviously weakened, especially within the first hour, probably due to the export activities of P-gp as reported [2] ( figure 5(d) ). However, red fluorescence of ADR-GO was clearly detected in the nucleus of MCF-7/ADR cells ( figure 5(e) ), indicating that GO loading only avoided depletion of ADR by MCF-7/ADR cells, but did not alter the subcellular location of ADR. Apparently, GO-loaded ADR could effectively enter MCF-7/ADR cells and locate in the nucleus by escaping the identification and export effects of P-gp, and therefore maintained the drug cytotoxicity.
GO could effectively carry the loads to enter MCF-7/ADR cells
A red-fluorescent dye, Dil, was used as a model drug to study the cell entry capability of GO for carrying drugs. Dil, a lipophilic tracer, shows strong fluorescence intensity in a hydrophobic environment, and weak fluorescence in an aqueous environment due to its poor solubility and self-quenching [30] . Thus it is often used as a biomembrane dye. In this study, Dil was loaded onto the surface of a GO sheet (Dil-GO) by π -π stacking and hydrophobic interactions. When the feed weight ratio of Dil to GO was 1/100, the loading content of Dil was about 0.0096 (0.96 wt%), representing a 96% loading efficiency. Dil-GO could emit strong red fluorescence even in aqueous solutions.
When MCF-7/ADR cells were treated with free Dil, the red fluorescence of Dil was mainly distributed in the cytomembrane (figures 6(a) and (b)), consistent with previous reports [30] . At 4 h, very weak fluorescence was also detected in the cytoplasm, suggesting that Dil molecules started to passively diffuse into cells. However, when cells were treated with Dil-GO, red fluorescence was mostly distributed in a uniform manner throughout the cytoplasm rather than the cytomembrane (figures 6(c) and (d)), and many hyperfluorescent dots were observed in the cells ( figure 6(d) ), which perhaps resulted from the aggregation of Dil-GO or affinity interactions of Dil-GO with cellular components. The significant difference in intracellular fluorescence distribution between Dil and Dil-GO suggested that GO could effectively carry drugs into cancer cells.
ADR-GO entered cancer cells in both endocytosis-dependent and independent manners
Two possible mechanisms may explain how GO-ADR enters cells. One is that GO-ADR attaches to the cytomembrane and enters cells through endocytosis. The other is that GO-ADR directly crosses the cytomembrane through passive diffusion. In order to distinguish these two pathways, ADR-GO treatment experiments were carried out at 4 • C. At this temperature the endocytosis was nearly blocked, and passive diffusion occurred at a relatively slow rate. As shown in figures 7(a) and (b), red fluorescence from ADR-GO was clearly detectable both in MCF-7 and MCF-7/ADR cells at 4 • C from 10 min to 4 h, suggesting that ADR-GO entered cells through an endocytosis-independent pathway. However, the fluorescence intensities in MCF-7 and MCF-7/ADR cells treated with ADR-GO for 4 h were significantly lower at 4 • C than at 37 • C, suggesting that endocytosis also played an important role in the cell entry process of ADR-GO. Moreover, the fluorescence intensity in MCF-7/ADR was significantly lower than that in MCF-7 cells at 37 • C ( figure 7(c) ), indicating that partial cellular ADR was exported outside cells by P-gp. But there was no significant difference in fluorescence intensities at 4 • C between in MCF-7 and in MCF-7/ADR cells ( figure 7(c) ), which was probably due to inhibition of the export effect of P-gp at low temperature. All the above results suggested that ADR-GO entered cancer cells in both endocytosis-dependent and independent manners. 
Drug resistance reversal mechanism of ADR-GO
Drug resistance is an obstacle to greater success with chemotherapy. Patients receiving chemotherapy can develop resistance to previously effective drugs to the point that the drugs are no longer effective. Thus, the reversal of drug resistance is always a major problem in cancer therapies. Recent investigations on the reversal of drug resistance mainly include the usage of P-gp selective antagonists, such as verapamil, cyclosporine, erythromycin, ketoconazole and tamoxifen [31] , and drug delivery by some novel nanoparticle systems [32] . However, these attempts are not satisfactory due to the high intrinsic toxicity, low drug loading capability and poor specificity for cancer.
Overexpression of P-gp, a membrane ATP-binding cassette transporter, is the main resistance mechanism of the MCF-7/ADR cells used in this study [33] . As shown in figure 8(a) , P-gp can use the energy released from ATP hydrolysis to pump a variety of anticancer drugs such as ADR out of the cells, called the 'export effect'. The avoidance of the export effect of P-gp is a major strategy for reversing drug resistance in breast cancer cells. Some nanoparticle carriers could enter cells via endocytosis and then accumulate in the cytoplasm by escaping the endosomal/lysosomal pathway, thus effectively reversing MDR in cancer cells due to the avoidance of export effects of P-gp [14] [15] [16] [17] . According to previous reports, GO can enter cells by endocytosis and then unload drug into the cytoplasm at low pH levels in endosomes (or lysosomes) [28] . In this study, the significant inhibition of cellular uptake of ADR-GO at 4 • C (figure 7) further confirmed this endocytosis pathway, and the pH-sensitive in vitro drug release behavior of ADR-GO (figure 2) suggested that ADR can be successfully released into the cytoplasm by the low endosomal pH triggers ( figure 8(b), I ). Thus, the export effects of surface expressed P-gp in MCF-7/ADR cells can be effectively avoided, manifested as the reversal of drug resistance ( figure 3) . Moreover, ADR-GO could still enter MCF-7/ADR cells under conditions of inhibited endocytosis at 4 • C (figure 7), indicating that there is another cell entry pathway for ADR-GO. We believed that this is direct passage across the cytomembrane by passive diffusion, which can also efficiently realize intracellular drug release ( figure 8(b) II) . Considering that the size distribution of prepared ADR-GO was non-uniform and a few ADR-GO sheets were smaller than 50 nm ( figure 1(b) ), we speculated that the dimensions of ADR-GO sheets may play an important role in their manner of cell entry. The larger size ADR-GO may be taken up by endocytosis, and the smaller size ADR-GO perhaps directly enters cells by passive diffusion across the cytomembrane just like small molecules. However, we still have not clarified the relationship between this direct cell entry pathway and the reversal effect of drug resistance, and related studies are in progress now.
3.8. Biosafety of GO used as a drug carrier for reversing drug resistance GO shows many advantages in cancer treatment, but biosafety is a main problem for its use as an anticancer drug carrier [34] . Some investigations have reported that GO is toxic for bacteria and mammalian cells, depending on its layer number, lateral size, stiffness, hydrophobicity, surface functionalization, and dose [35, 36] . Limited in vivo studies demonstrated that GO is predominantly deposited in the lungs and retained for a long time [37] , and exhibits dose-dependent toxicity to animals, such as the formation of lung granuloma, and cannot be cleaned out by the kidney [28] . However, recent investigations also found that the in vitro and in vivo toxicities of GO with a biocompatible coating (e.g. PEGylation [19] and protein adsorption [38] ) are significantly reduced. In our study, GO showed no detectable cytotoxicity in the concentration range used. Moreover, GO was nearly surface-modified with ADR molecules due to high drug loading content, which was clearly observed by AFM in our previous report [24] . Taken together, whether GO can be used as a drug carrier for reserving drug resistance in cancer cells still needs further investigations.
Conclusion
In summary, this study investigated the reversal of drug resistance in MCF-7/ADR cells using GO as the carrier for ADR. ADR-GO with high drug loading content was prepared and its pH-sensitive release behavior was evaluated in vitro. ADR-GO could enter MCF-7/ADR cells by both endocytosis and passive diffusion, thus realizing efficient intracellular drug release by avoiding the export effects of surface P-gp. The results suggested that use of GO as a carrier of chemotherapeutic drugs is favorable for the treatment of drug resistant cancers, and the further investigations are in progress now.
